Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

NCT ID: NCT03099785

Last Updated: 2021-01-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 279 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-18
• Study Completion Date: 2020-12-14

Brief Summary

The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX® 600 mg tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered two to three times daily.

Conditions

Diarrhea-predominant Irritable Bowel Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Treatment group 1: dose regimen 1

Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)

Group Type: ACTIVE_COMPARATOR

Rifamycin SV 600mg t.i.d.

Intervention Type: DRUG

Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet

Treatment group 2: dose regimen 2

Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)

Group Type: ACTIVE_COMPARATOR

Rifamycin SV b.i.d. + Placebo

Intervention Type: DRUG

Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet

Treatment group 3: matching placebo

Rifamycin SV-MMX® matching placebo tablets, t.i.d.

Group Type: PLACEBO_COMPARATOR

Placebo t.i.d.

Intervention Type: DRUG

Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet

Interventions

Rifamycin SV 600mg t.i.d.

Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet

Intervention Type: DRUG

Rifamycin SV b.i.d. + Placebo

Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet

Intervention Type: DRUG

Placebo t.i.d.

Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Informed Consent: signed written informed consent before inclusion in the study

2. Sex and Age: males/females, ≥18 year old

3. IBS Diagnosis: confirmed IBS-D diagnosis per Rome IV criteria

4. Symptoms: active symptoms of IBS at baseline (day 1) as measured by average daily scores for at least 7 days before baseline:

1. abdominal pain score ≥3 using an 11-point numeric rating scale and

2. bloating score: 2-4 inclusive and

3. stool consistency: score 6 or 7 (measured by the Bristol stool form scale) for at least 2 days from day -7 to day -1

and by a negative response to the global IBS symptom assessment question and to the IBS-related bloating assessment question both given weekly during the screening phase up to day 1 before randomisation:

4. "In the past 7 days, have you had adequate relief of your IBS symptoms?" [No] and

5. "In the past 7 days, have you had adequate relief of your IBS symptom of bloating?"[No]

5. Colonoscopy: performed within 5 years; if patient's age >50, colonoscopy performed within 2 years

6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the study

7. Literacy: sufficiently literate to comply with the study requirement of using electronic diaries and filling in electronic forms

8. Contraception and fertility: females of childbearing potential and fertile males must be using at least one reliable method of contraception.

Reliable methods of contraception for women include:

1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit

2. A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit

Reliable methods of contraception for men and male partners of female patients include:

3. Male condoms with spermicide

Reliable methods of contraception for both women and men include:

4. A sterile sexual partner or sexual abstinence Women of non-childbearing potential or in post-menopausal status for at least 1 year and sterile or surgically sterilised men will be admitted.

For women of childbearing potential, serum pregnancy test result must be negative at screening

Exclusion Criteria

1. IBS: symptoms of constipation at baseline:

1. less than 3 bowel movements a week and

2. stool consistency score ≤2 for ≥2 days in a week

2. Screening phase: failure to record the daily symptom assessments in the diary cards for at least 7 days before baseline

3. Gastroenteric: underlying gastrointestinal diseases including ulcerative colitis, Crohn's disease, pancreatitis, any active infectious, haemorrhagic or inflammatory disorder not related to IBS-D, gastrointestinal motility disorders such as ileus, gastroparesis or pseudoobstruction, gastroduodenal ulcer, gastrointestinal malignancy or potentially fatal diseases if not full in remission (5 years from diagnosis and without maintenance treatment), amyloidosis and cholelithiasis if cholecystectomy not performed

4. Intolerance: ascertained underlying lactose intolerance with response to diet or any other malabsorption syndrome with the exclusion of asymptomatic lactose malabsorption

5. Coeliac disease: ascertained or presumptive underlying coeliac disease

6. Bile: ascertained or presumptive bile acid malabsorption or bile acid induced diarrhoea

7. Diabetes: underlying diabetes type I or II

8. Thyroid: abnormal thyroid function not controlled by thyroid medications

9. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study

10. Renal function: ascertained or presumptive clinically significant renal insufficiency or creatinine above twice the upper limit of normal (ULN) of the performing laboratory reference range

11. Liver function: chronic liver disease or clinically significant liver enzyme abnormality as evidenced by elevated AST, ALT or total bilirubin >1.5 times ULN

12. AIDS/HIV: ascertained or presumptive acquired immunodeficiency (AIDS) or known infection with human immunodeficiency virus (HIV)

13. Diseases: significant history of medical or surgical conditions excluding hysterectomy, caesarean section, appendectomy, cholecystectomy, benign polypectomy and inguinal hernia and including renal, hepatic, cardiovascular, haematological, endocrine, immune, psychiatric or neurological diseases that in the investigator's opinion may interfere with the aim of the study; malignant diseases not in remission for at least 5 years

14. Medications: alosetron, eluxadoline, ondansetron, tegaserod, lubiprostone, warfarin, antipsychotic, antispasmodic, prokinetic, antidiarrhoeal, laxative, probiotic, narcotic or antibiotic agents within 14 days before the screening visit; antidepressant agents of the selective serotonin-reuptake inhibitor and tricyclic classes unless taken at a stable dose for at least 6 weeks before the screening visit

15. Investigational drugs: participation in the evaluation of any investigational product within 30 days before this study

16. Drug and alcohol: known history of drug or alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to the USDA Dietary Guidelines 2015] abuse

17. Pregnancy (females only): pregnant or lactating women or wishing to become pregnant in the 3 months following this visit

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cosmo Technologies Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University Hospital Gasthuisberg, Department of Gastroenterology

Leuven, Herestraat 49, Belgium

St Lukas Ziekenhuis,

Bruges, Lucaslaan 29, Belgium

Clinique universitaires Saint-Luc Gastroenterologie Route 606 Avenue Hippocrate, 10

Brussels, , Belgium

Maria Middelares, Digestief Centrum, Buitenring St-Denijs 30

Ghent, , Belgium

University Hospital Gent, Depintelaan 185

Ghent, , Belgium

Emovis GmbH Wilmersdorfer Straße 79

Berlin, , Germany

Unterfrintroper Hausarztzentrum Lehrpraxis der Universität Essen

Essen, , Germany

Internistenzentrum Bahnhofstrasse 30

Gauting, , Germany

Clinical Research Hamburg GmbH, Rahlstedter Bahnhofstraße 33

Hamburg, , Germany

Gastroenterologie, Interventionelle Endoskopie, Diabetologie und Akutgeriatrie, KRH-Zentrumsgeschaftsfuhrer innere Medizin, KRK Klinikum Siloah-Oststadt-Heidehaus Stadionbrucke 4

Hanover, , Germany

Gemeinschaftspraxis Dr. Klein & J. Minnich

Künzing, , Germany

AmBeNet GmbH, Wilhelm-Leuschner-Platz I2,

Leipzig, , Germany

Universitatsklinikum Magdeburg A.O.R. Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Leipziger Str.44

Magdeburg, , Germany

Ärztehaus Reinfeld Praxisgemeinschaft für Allgemeinmedizin Klosterstraße 7

Reinfeld, , Germany

Innomed Dr. med. Naudts Ludwig-Erhard-Platz 11

Rodgau, , Germany

Internistische Praxisgemeinschaft, Bereich Gastroenterologie Hauptstraße. 51

Weyhe, , Germany

S.O.C Gastroenterologia Oncologica

Aviano, PN, Italy

Azienda Ospedaliera G. Brotzu, U.O. di Gastroenterelogia, Via Peretti

Cagliari, , Italy

Istituto Clinico Humanitas, Centro Malattie Infiammatorie Croniche Intestinali

Milan, , Italy

Fonazione IRCCS Ospedale Maggiore

Milan, , Italy

Fondazione IRCCS Policlinico S. Matteo, Dip Area Medica: Medicina Generale 1, Viale Camillo Golgi, 19

Pavia, , Italy

Polo Scienze Gastroenterologiche ed

Roma, , Italy

Universita Campus Bio Medico, U.O.C di Gastroenterologia ed Endoscopia Digestiva

Roma, , Italy

IRCCS Policlinico San Donato, Medicina Generale III- Gastroenterologia

San Donato Milanese, , Italy

Hospital Universitari Germans Trias i Pijol (Can Ruti). Servicio de Aparto Digestivo Carretera de Canyet, s/n

Badalona, Barcelona, Spain

Hospital Universitario La Paz, Servicio de Aparato Digestivo Po de la Castellana 261

Castellana, Madrid, Spain

Hospital Universitario Ramon Y Cajal, Servicio de Gastroenterologia y Hepatologia Ctra. de colmenar Viejo, Km 9,100

Colmenar Viejo, Madrid, Spain

Hospital Universitari vall d'Hebron, Servicio de Aparato Digestivo, Passeig Vall d'Hebron, 119-129

Barcelona, , Spain

Hospital Universitario Clinico San Carlos, Servicio de Aparato Digestivo, Calle del Prof Martin Lagos, s/n,

Madrid, , Spain

Countries

Belgium; Germany; Italy; Spain

Other Identifiers

CB-01-11/28

Identifier Type: -

Identifier Source: org_study_id